VACCINEX INC
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
VCNX$1.41-61.4%Stored close · as of Dec 17, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
(in thousands, except share and per share data)
| As of December 31, 2024 | As of December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,107 | $1,535 |
| Accounts receivable | 838 | 961 |
| Prepaid expenses and other current assets | 586 | 853 |
| Derivative asset | - | - |
| Total current assets | 2,531 | 3,349 |
| Property and equipment, net | 65 | 136 |
| Operating lease right-of-use asset | - | 146 |
| TOTAL ASSETS | $2,596 | $3,631 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,955 | $2,039 |
| Accrued expenses | 1,104 | 1,242 |
| Deferred revenue | - | 63 |
| Current portion of long-term debt | 25 | 75 |
| Operating lease liability | - | 146 |
| Warrant liability | - | 2,351 |
| Total current liabilities | 5,084 | 5,916 |
| Long-term debt | - | 26 |
| TOTAL LIABILITIES | 5,084 | 5,942 |
| Stockholders’ equity (deficit): | ||
| Convertible preferred stock (Series A), par value of $0.001 per share; 10,000,000 shares authorized, 10 shares issued and outstanding as of December 31, 2024, and no shares authorized, issued or outstanding as of December 31, 2023; with aggregate liquidation preference of $1,750,000 and $0 as of December 31, 2024 and December 31, 2023, respectively | 1,665 | - |
| Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of December 31, 2024, and December 31, 2023; 2,676,642 and 892,622 shares issued as of December 31, 2024 and December 31, 2023, respectively; 2,676,637 and 892,617 shares outstanding as of December 31, 2024 and December 31, 2023, respectively | 1 | - |
| Additional paid-in capital | 354,418 | 337,627 |
| Treasury stock, at cost; 5 shares of common stock as of December 31, 2024, and December 31, 2023, respectively | (11) | (11) |
| Accumulated deficit | (358,561) | (339,927) |
| TOTAL STOCKHOLDERS’ EQUITY/(DEFICIT) | (2,488) | (2,311) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $2,596 | $3,631 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.